Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry

Key Points

• This research aims to evaluate the feasibility and clinical outcomes of retreating NSCLC patients with selective RET inhibitors after previous treatment failures.
• Patients were pretreated with selpercatinib or pralsetinib.
• Identified cases of toxicity leading to SRI switch were analyzed.
• Observed outcomes post-rechallenge focusing on disease progression.
• Switching SRI after toxicity is feasible and active in certain patient groups.
• Overall efficacy of SRI rechallenge was limited.
• Patients with brain-only or oligoprogressive disease showed some potential benefit.

Abstract